Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068409 | 0.77 | MAPT (1.00) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21799330 | 0.76 | MAPT (0.97) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL6200142 | 0.76 | MAPT (0.49) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL4594845 | 0.74 | KIF11 (0.68) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL18198323 | 0.71 | ALDH1A1 (0.56) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL26613494 | 0.71 | MAPT (0.56) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL7314031 | 0.71 | MAPT (1.00) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL8525270 | 0.71 | SMN1; SMN2 (0.70) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL18114131 | 0.71 | MAPT (0.56) | MAPTALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL25857004 | 0.71 | MAPT (0.46) | MAPTALDH1A1POLBHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277678-B1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20180086752-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086752-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086752-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3277678-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NantBioScience, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016161361-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIOSCIENCE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161361-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIOSCIENCE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086752-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | KRAS, NRAS, HRAS | MAPT 4029/4885ALDH1A1 4472/4885POLB 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.